Hanwha Becomes World’s First to Successfully Demonstrate a 59.5% Hydrogen Co-firing Rate in 80-megawatt-class Gas Turbines

□ Hanwha successfully conducted the world’s highest hydrogen co-firing rate test on medium- to large-sized (80 megawatt) gas turbines while significantly reducing carbon dioxide (CO2) and nitrogen oxide (NOx) emissions. □ By retrofitting stranded LNG-fired power generation facilities to run on a mixture of hydrogen fuel and LNG, the company’s hydrogen co-firing technology can mitigate the risk of gas turbines becoming stranded assets. Hanwha has become the world’s first to successfully demonstrate hydrogen co-firing of up to 59.5% in an 80-megawatt-class gas turbine, with significantly reduced carbon dioxide (CO2) and nitrogen oxide (NOx) emissions. This is the highest recorded co-firing rate on a medium- to large-sized gas turbine capable of commercial operation, and is expected to accelerate the commercialization of hydrogen co-fired eco-friendly power generation. For the co-firing test, Hanwha worked with Korea Western Power – a subsidiary of the country’s state-run power supplier KEPCO – on research and development of retrofitting the 80 MW gas turbine. The technology was able to reduce CO2 emissions by 22% compared to LNG-fired power generation, and limited NOx emissions to 6 parts per million (ppm) – just 30% of the 20 ppm deemed acceptable by European standards – without an additional reduction device. “Co-firing power generation is an intermediate step towards carbon-free power generation,” said Hanwha Impact CEO Hee-chul Kim. “This method will serve as a key stepping stone to carbon neutrality.” Also attending the ceremony, which took place at the Hanwha Impact Daesan plant, were the CEOs of Hanwha Power Systems, Hanwha Corp. E&C, and Hanwha TotalEnergies Petrochemical, alongside members of government and academia. Hanwha’s hydrogen to gas turbine technology (H2GT) contributes to environmental sustainability while also creating economic value. When applied to existing LNG-fired gas turbines, this technology can mitigate the risk of gas turbines becoming stranded assets by retrofitting the plants to utilize a mixture of hydrogen and gas. The hybrid solution is also estimated to extend the lifespan of aging LNG-fired gas turbine parts by more than 20 years. Hanwha will continue to develop its hydrogen co-firing technology with the goal of attaining 100% hydrogen power generation in gas-fired turbines. Key to the success of the latest co-firing test was Hanwha’s world-class hydrogen combustor and flame control technologies. Emissions control is more challenging when burning hydrogen as its flame temperature is significantly higher than LNG, and this in turn drives up NOx emissions. Using its combustor technology, Hanwha was able to control combustion conditions without an additional reduction device to significantly reduce harmful emissions. In addition, its flashback control technology ensured stable power generation with an increased hydrogen co-firing rate by reducing what is known as combustion flashback – a condition that sends the flame back up against the burn tube, causing damage to stable output.

Hanwha Impact Invests in Gene Writing™ Pioneer Tessera Therapeutics to Drive the Future of Genetic Medicine

Hanwha Impact recently announced its investment in Tessera Therapeutics, an American life sciences company that is pioneering a new category of genome engineering technology and establishing a new field of genetic medicine. The company was founded in 2018 by Flagship Pioneering, the investor behind COVID-19 vaccine maker Moderna. Tessera recently secured $300 million in a Series C financing, the fourth stage of startup financing that focuses on scaling successful companies, where Hanwha Impact participated as an investor. Tessera is known for its next-generation gene correction technology platform called Gene Writing™, which utilizes Mobile Genetic Elements (MGEs)1 to overcome the limitations of existing technology. As the technology supports the design and testing of numerous natural and synthetic MGEs, Gene Writing™ is perceived to be more accurate and efficient than the existing gene correction techniques using CRISPR/Cas92. By targeting DNA, the code of life and cause of genetic diseases, Gene Writing™ can write into or rewrite the genome to treat health conditions at their source. The company’s technology can change base pairs, make small insertions or deletions, and integrate entire genes into the genome. Gene Writing™ could lead to a cure for all manner of genetic disorders, including those that are rare and currently untreatable with existing genetic technologies. “Tessera’s Gene Writing™ platform aims to develop a fundamentally different technology than conventional gene therapeutics,” said Noubar Afeyan, the co-founder and chairman of Tessera and Moderna and the founder and CEO of Flagship Pioneering. “The funds raised this time will be used to realize the potential cure for genetic diseases.” In 2021, Hanwha Impact invested in Inari Agriculture, an AgTech firm utilizing gene-editing technology. Inari Agriculture uses Artificial Intelligence (AI) and gene editing to develop seeds that generate a smaller carbon footprint and increase yield by using 40% less water and fertilizer. Hanwha Impact has a vision of making a positive impact on the globe and humanity for a sustainable future through technical innovation. Hanwha Impact plans to continue actively investing in companies and technologies like Tessera Therapeutics and Inari Agriculture that push the boundaries of what is possible with technology for a better, healthier tomorrow. ¹ Mobile Genetic Elements (MGEs), also called as transposons or “jumping genes,” refer to a type of DNA sequence that can move around within a genome. Approximately 50% of the human genome and 90% of the plant genome are thought to be MGEs. This was first discovered by Barbara McClintock, a US cytogeneticist, in 1944 while observing the color changes of maize. She countered the traditional genetic theory that genes stayed fixed to chromosomes. Her contributions were recognized with a Nobel Prize in Physiology or Medicine in 1983. ² Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is a family of short DNA sequences found in the genomes of prokaryotic organisms. Hanwha Impact Hanwha Impact is leading the charge for a net-zero future with low carbon, sustainable energy and innovative future-ready projects. A subsidiary of Hanwha Solutions, the company secures revolutionary technologies through a range of business development and open innovation via active mergers, acquisitions and strategic investments. Hanwha Impact aims to lead the Fourth Industrial Revolution through forward-thinking innovations in the fields of eco-friendly energy, technology convergence, mobility, and aerospace. Tessera Therapeutics Tessera Therapeutics is pioneering Gene Writing™ technology, which consists of multiple technology platforms designed to offer scientists and clinicians the ability to write therapeutic messages into the human genome, thereby curing diseases at their source. The Gene Writing platform allows the correction of single nucleotides, the deletion or insertion of short sequences of DNA, and the writing of entire genes into the genome, offering the potential for a new category of genetic medicines with broad applications both in vivo and ex vivo. Tessera Therapeutics was founded by Flagship Pioneering in 2018, a life sciences innovation enterprise that conceives, resources and develops first-in-category companies to transform human health and sustainability. For more information, visit: www.tesseratherapeutics.com

Hanwha provides a Hydrogen fuel-flexible retrofit solution to support decarbonization of Uniper gas turbine power plant

Hanwha will retrofit one of Uniper’s Rotterdam Capelle (RoCa) power plant’s gas turbines with their HyFlex LEC-III™ combustion system, capable of being operated with a variable blend of hydrogen (H2) and natural gas fuel. The RoCa power plant, located in the Zuid-Holland Province of The Netherlands, has a net electrical output of 264MW. It has two Frame 5 gas turbines commissioned in 1983 (RoCa 1 & 2) and one Frame 9E (RoCa3), manufactured by Thomassen, commissioned in 1996. In 2023, Uniper is planning to switch the RoCa plant’s fuel source from Groningen natural gas to a high caloric gas supply. To support their desired gas-fired power decarbonization objectives, Uniper anticipates blending the new gas supply with upwards of 30% H2. When installed into the RoCa3 Frame 9E turbine in early 2023, Thomassen’s HyFlex LEC-III™ combustion retrofit system, developed jointly with their sister company PSM, based in the US, will be capable of handling this enhanced fuel flexibility requirement with ultra-low emissions when coupled with the delivery of their combustion AutoTune digital solution. Peter Stuttaford, CEO of Thomassen Energy: “Our H2 fuel-flex retrofit solution selected by Uniper for RoCa3 has been operating successfully on three (3) Frame 9E turbines in the Netherlands at another